Cempra Inc. (CEMP) Drops 5.22% on January 18

Equities Staff |

Cempra Inc. (CEMP) was one of the Russell 2000's biggest losers for Monday January 18 as the stock slid 5.22% to $20.34, a loss of $-1.12 per share. Starting at an opening price of $19.79 a share, the stock traded between $19.50 and $21.11 over the course of the trading day. Volume was 1.14 million shares over 7,879 trades, against an average daily volume of 1.51 million shares and a total float of 43.97 million.

The losses send Cempra Inc. down to a market cap of $894.28 million. In the last year, Cempra Inc. has traded between $46.99 and $15.43, and its 50-day SMA is currently $28.61 and 200-day SMA is $32.90.

Cempra Inc is a clinical-stage pharmaceutical company. It develops antibiotics for acute care & community settings to meet critical medical needs in treatment of bacterial infectious diseases, respiratory tract & chronic staphylococcal infections.

Cempra Inc. is based out of Chapel Hill, NC and has some 55 employees. Its CEO is Prabhavathi Fernandes.

For a complete fundamental analysis analysis of Cempra Inc., check out Equities.com’s Stock Valuation Analysis report for CEMP. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

AfterMaster Inc

Studio One Media Inc is a diversified media and technology company. It is engaged in the development and commercialization of proprietary, edge audio and video technologies for professional and consumer…

Private Markets

BioSculpture Technology, Inc.

BioSculpture Technology, Inc. (“BST”) is a commercial-stage medical device manufacturer of liposuction surgical instruments for surgeons. It offers the FDA-cleared Twin Cannula Assisted Liposuction ("TCAL") Airbrush Liposculptor II® controllers, Airbrush®…

Ozobot by Evollve Inc

Ozobot is a world leader in compact super intelligent robots that entertain and educate through fun interactive gaming.